SCHEMBL6790717

SCHEMBL6790717

CCOC(=O)c1c2c(nn1CCCNCCc1cccs1)C1=C(CC2)NN(C(c2ccccc2)(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
NPC1 O15118 5/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.34
HPGD P15428 4/20 0.34
RAB9A P51151 4/20 0.34
P2RY12 Q9H244 2/20 0.34
CYP2D6 P10635 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC26A6 Q9BXS9 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.31
PDE4D Q08499 1/20 0.31
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795358 0.87 ADORA3 (0.33) ALDH1A1NPC1KDM4ESMN1; SMN2HPGD
SCHEMBL6791964 0.82 KDM4E (0.35) KDM4EMAPTNPSR1DRD2
SCHEMBL6793102 0.82 ALDH1A1 (0.35) ALDH1A1NPC1KDM4ESMN1; SMN2HPGD
SCHEMBL6790712 0.81 P2RY12 (0.34) ALDH1A1NPC1KDM4ESMN1; SMN2HPGD
SCHEMBL6798586 0.81 MAPT (0.34) ALDH1A1KDM4ESMN1; SMN2HPGDGAA
SCHEMBL6798838 0.79 ADORA1 (0.35) NPC1KDM4ESMN1; SMN2RAB9AMAPT
SCHEMBL6793133 0.79 KMT2A (0.40) ALDH1A1KDM4ESMN1; SMN2HPGDCYP1A2
SCHEMBL6794842 0.77 OPRD1 (0.35) ALDH1A1NPC1KDM4ESMN1; SMN2HPGD
Trifluoroacetic Acid SCHEMBL6793066 0.75 ROCK2 (0.38) ALDH1A1NPC1KDM4ESMN1; SMN2HPGD
SCHEMBL6792562 0.70 AURKA (0.51) ALDH1A1NPC1KDM4EHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 PHARMACIA CORPORATION 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127492-A1 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 MKNK2, MAPKAPK2, MAP3K2 ALDH1A1 4449/4885NPC1 4242/4885KDM4E 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.